With six antibiotic products in different stages of research and launch in its basket, drugmaker Wockhardt has set up an antibiotic academy to dialogue with practitioners to share real-world clinical data and promote the rational use of antibiotics, said Founder Chairman Habil Khorakiwala.
SENSEX 78,542.44
+ 43.27
NIFTY 24,583.80
+ 13.15
CRUDEOIL 7,675.00
The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic for…
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase…
Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an…
Zydus receives USFDA approval for a surgical imaging drug, Indocyanine Green, with a 180-day exclusivity window for marketing.
They called for a “transparent, time-bound, and conflict of interest-free process to revise the NLEM, ensuring that it reflects…
Wockhardt has launched the Antibiotic Academy, an open scientific learning platform to strengthen clinical dialogue and…
